Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Plavix Settlement Outcome May Make Industry Overly Cautious, Legal Experts Say

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Collapse of Bristol/Sanofi generic settlement with Apotex will likely impact future brand-generic negotiations, attorneys predict.

You may also be interested in...



FTC Enjoins Warner Chilcott From Providing “Anything Of Value” To ANDA Filers

Commission settles charges against the brand drug maker related to generic Ovcon 35.

FTC Enjoins Warner Chilcott From Providing “Anything Of Value” To ANDA Filers

Commission settles charges against the brand drug maker related to generic Ovcon 35.

Apotex Alleges Bristol/Sanofi Misled Regulators On Plavix Settlement

Bristol/Sanofi made oral commitments to Apotex that were not included in a written settlement, Apotex claims in court documents.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS063201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By